Amicus Therapeutics (NASDAQ:FOLD – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, March 1st. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Amicus Therapeutics Stock Down 3.2 %
FOLD stock opened at $12.88 on Wednesday. Amicus Therapeutics has a 52-week low of $5.91 and a 52-week high of $13.61. The company’s 50 day simple moving average is $12.51 and its 200-day simple moving average is $11.67. The company has a debt-to-equity ratio of 2.95, a current ratio of 2.78 and a quick ratio of 2.70. The firm has a market capitalization of $3.62 billion, a P/E ratio of -14.00 and a beta of 0.86.
Insider Transactions at Amicus Therapeutics
In other news, CEO Bradley L. Campbell sold 5,485 shares of the stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $12.20, for a total transaction of $66,917.00. Following the transaction, the chief executive officer now owns 689,618 shares in the company, valued at approximately $8,413,339.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Bradley L. Campbell sold 5,485 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $12.20, for a total value of $66,917.00. Following the transaction, the chief executive officer now owns 689,618 shares of the company’s stock, valued at $8,413,339.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman John F. Crowley sold 11,347 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $12.20, for a total transaction of $138,433.40. Following the completion of the transaction, the chairman now directly owns 801,922 shares in the company, valued at approximately $9,783,448.40. The disclosure for this sale can be found here. Insiders have sold a total of 386,683 shares of company stock worth $4,847,217 in the last 90 days. 2.40% of the stock is owned by insiders.
Hedge Funds Weigh In On Amicus Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Alliancebernstein L.P. grew its stake in Amicus Therapeutics by 0.4% during the fourth quarter. Alliancebernstein L.P. now owns 315,929 shares of the biopharmaceutical company’s stock worth $3,857,000 after buying an additional 1,200 shares during the last quarter. Point72 Middle East FZE acquired a new position in shares of Amicus Therapeutics during the fourth quarter valued at $81,000. State of Wyoming bought a new stake in Amicus Therapeutics during the 4th quarter worth about $198,000. Metropolitan Life Insurance Co NY lifted its position in Amicus Therapeutics by 4.9% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 16,962 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 797 shares during the period. Finally, MetLife Investment Management LLC lifted its position in Amicus Therapeutics by 0.7% during the 4th quarter. MetLife Investment Management LLC now owns 146,423 shares of the biopharmaceutical company’s stock valued at $1,788,000 after purchasing an additional 947 shares during the period.
Analysts Set New Price Targets
FOLD has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on shares of Amicus Therapeutics from $14.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday, November 8th. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 31st. Finally, BTIG Research upped their price objective on shares of Amicus Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, January 18th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.